Korsana Biosciences, Inc. (KRSA)
Korsana Biosciences is developing CYC-126, a personalized anesthesia treatment for depression that has not responded to standard antidepressants. It last closed at $32.50 on Nov 17, down 0.55% on the day. The average 12-month price target from 5 analysts is $51.20 (+57.5% from the last close), with a high of $70.00 and a low of $43.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $789K, the largest $789K.
Key Stats
Last 12 monthsNot reported for this period.
From KRSA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 5 analysts who set a price target on KRSA in the past 90 days. The average target is $51.20, with a high of $70.00 and a low of $43.00, compared with the last close of $32.50.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Wells Fargo | Initiated | Buy | $44 |
| Oct 5 | Wedbush | Initiated | Buy | $44 |
| Sep 28 | Guggenheim | Initiated | Buy | $70 |
| Sep 14 | Stifel | Initiated | Buy | $43 |
| Sep 11 | UBS | Initiated | Buy | $55 |
Technical Analysis
The stock is 3% above its 20 day and 2% above its 50 day average. It is 28% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 54). The nearest support is the Pivot at $32.09, and the nearest resistance the swing high (Nov 4) at $33.44.
| RSI (14) | 54.42 | Middle of its range | Neutral |
| MACD | 0.11 | Above its signal line | Bullish |
| Stochastic | 64.0 | Middle of its range | Neutral |
| ADX (14) | 13.0 | No clear trend | |
| Williams %R | -34.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 70.0 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +1.7% | Change over 10 sessions | Bullish |
| ATR (14) | $2.26 | Typical daily range, 7.0% of price |
| RSI (14) | 60.47 | Strong, overbought above 70 | Neutral |
| MACD | 2.82 | Below its signal line | Bearish |
| Stochastic | 68.4 | Middle of its range | Neutral |
| ADX (14) | 58.4 | Strong uptrend | |
| Williams %R | -27.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 70.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +1.9% | Change over 10 sessions | Bullish |
| ATR (14) | $4.91 | Typical daily range, 15.1% of price |
What happened before
See how KRSA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How KRSA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in KRSA in the last 90 days.
Dark Pool
30DKRSA Institutional Ownership
Full report →- ▲43 buying vs 0 selling
- ▲Held by funds +86.7 pts
- ●Funds holding +44
- ▲Superinvestors: 3 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 44 | – | – |
| In funds' top 10 | 9 | – | – |
| Held by funds | 86.7% | – | – |
| New / increased | 43 / 0 | – | – |
| Reduced / sold out | 0 / 0 | – | – |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KRSA is in one of them and how their past KRSA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered KRSA in an article yet. Here's the latest on the wider market.
About Korsana Biosciences
Korsana Biosciences is a drug developer based in Waltham, Massachusetts, focused on serious neuropsychiatric disorders. Its lead program, CYC-126, is being developed as a treatment for depression that has not responded to at least two antidepressant treatments. The approach combines two widely used anesthetic agents, propofol and dexmedetomidine, with a delivery system that monitors brain activity so dosing can be tailored to each patient. It is designed for use in hospital settings under the care of anesthesiologists. The company is also working to license its older sGC stimulator assets to other firms.
- Headquarters
- Waltham, MA

